Cargando…

COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-

Objective: Glioblastoma (GBM) and Primary Central Nervous System Lymphoma (PCNSL) are common intracranial malignant tumors. They sometimes present similar radiological findings and diagnoses could be difficult without surgical biopsy. For improving the current management, development of non-invasive...

Descripción completa

Detalles Bibliográficos
Autores principales: Onishi, Shumpei, Yamasaki, Fumiyuki, Takano, Motoki, Yonezawa, Ushio, Sugiyama, Kazuhiko, Tahara, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699101/
http://dx.doi.org/10.1093/noajnl/vdaa143.093
_version_ 1783615971866443776
author Onishi, Shumpei
Yamasaki, Fumiyuki
Takano, Motoki
Yonezawa, Ushio
Sugiyama, Kazuhiko
Tahara, Hidetoshi
author_facet Onishi, Shumpei
Yamasaki, Fumiyuki
Takano, Motoki
Yonezawa, Ushio
Sugiyama, Kazuhiko
Tahara, Hidetoshi
author_sort Onishi, Shumpei
collection PubMed
description Objective: Glioblastoma (GBM) and Primary Central Nervous System Lymphoma (PCNSL) are common intracranial malignant tumors. They sometimes present similar radiological findings and diagnoses could be difficult without surgical biopsy. For improving the current management, development of non-invasive biomarkers are desired. In this study, we explored the differently expressed circulating small noncoding RNA (sncRNA) in serum for specific diagnostic tool of GBM and PCNSL. Material & Methods: Serum samples were obtained from three groups: 1) GBM patients (N=26), 2) PCNSL patients (N=14) 3) healthy control (N=114). The total small RNAs were extracted from serum. The whole expression profiles of serum sncRNAs were measured using Next-Generation Sequencing System. We analyzed serum levels of sncRNAs (15–55 nt) in each serum samples. The difference of sncRNAs expression profile among three groups were compared. Data analysis was performed by logistic regression analysis followed by leave-one-out cross-validation (LOOCV). The accuracy of diagnostic models of sncRNAs combination were evaluated by receiver operating characteristic (ROC) analysis. Results: We created the combination models using three sncRNA in each models based on the logistic regression analysis. The model 1 (based on sncRNA-X1, X2 and X3) enabled to differentiate GBM patients form healthy control with a sensitivity of 92.3% and a specificity of 99.2% (AUC: 0.993). The model 2 (based on sncRNA-Y1, Y2 and Y3) enabled to differentiate PCNSL patients form healthy control with a sensitivity of 100% and a specificity of 93.9% (AUC: 0.984). The model 3 (based on sncRNA-Z1, Z2 and Z3) enabled to differentiate GBM patients form PCNSL patients with a sensitivity of 92.3% and a specificity of 78.6% (AUC: 0.920). Conclusion: We found three diagnostic models of serum sncRNAs as non-invasive biomarkers potentially useful for detection of GBM and PCNSL from healthy control, and for differentiation GBM from PCNSL.
format Online
Article
Text
id pubmed-7699101
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-76991012020-12-02 COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA- Onishi, Shumpei Yamasaki, Fumiyuki Takano, Motoki Yonezawa, Ushio Sugiyama, Kazuhiko Tahara, Hidetoshi Neurooncol Adv Supplement Abstracts Objective: Glioblastoma (GBM) and Primary Central Nervous System Lymphoma (PCNSL) are common intracranial malignant tumors. They sometimes present similar radiological findings and diagnoses could be difficult without surgical biopsy. For improving the current management, development of non-invasive biomarkers are desired. In this study, we explored the differently expressed circulating small noncoding RNA (sncRNA) in serum for specific diagnostic tool of GBM and PCNSL. Material & Methods: Serum samples were obtained from three groups: 1) GBM patients (N=26), 2) PCNSL patients (N=14) 3) healthy control (N=114). The total small RNAs were extracted from serum. The whole expression profiles of serum sncRNAs were measured using Next-Generation Sequencing System. We analyzed serum levels of sncRNAs (15–55 nt) in each serum samples. The difference of sncRNAs expression profile among three groups were compared. Data analysis was performed by logistic regression analysis followed by leave-one-out cross-validation (LOOCV). The accuracy of diagnostic models of sncRNAs combination were evaluated by receiver operating characteristic (ROC) analysis. Results: We created the combination models using three sncRNA in each models based on the logistic regression analysis. The model 1 (based on sncRNA-X1, X2 and X3) enabled to differentiate GBM patients form healthy control with a sensitivity of 92.3% and a specificity of 99.2% (AUC: 0.993). The model 2 (based on sncRNA-Y1, Y2 and Y3) enabled to differentiate PCNSL patients form healthy control with a sensitivity of 100% and a specificity of 93.9% (AUC: 0.984). The model 3 (based on sncRNA-Z1, Z2 and Z3) enabled to differentiate GBM patients form PCNSL patients with a sensitivity of 92.3% and a specificity of 78.6% (AUC: 0.920). Conclusion: We found three diagnostic models of serum sncRNAs as non-invasive biomarkers potentially useful for detection of GBM and PCNSL from healthy control, and for differentiation GBM from PCNSL. Oxford University Press 2020-11-28 /pmc/articles/PMC7699101/ http://dx.doi.org/10.1093/noajnl/vdaa143.093 Text en © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Onishi, Shumpei
Yamasaki, Fumiyuki
Takano, Motoki
Yonezawa, Ushio
Sugiyama, Kazuhiko
Tahara, Hidetoshi
COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
title COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
title_full COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
title_fullStr COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
title_full_unstemmed COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
title_short COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
title_sort cot-04 circulating biomarker for glioblastoma and primary central nervous system lymphoma -next generation sequencing of small noncoding rna-
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699101/
http://dx.doi.org/10.1093/noajnl/vdaa143.093
work_keys_str_mv AT onishishumpei cot04circulatingbiomarkerforglioblastomaandprimarycentralnervoussystemlymphomanextgenerationsequencingofsmallnoncodingrna
AT yamasakifumiyuki cot04circulatingbiomarkerforglioblastomaandprimarycentralnervoussystemlymphomanextgenerationsequencingofsmallnoncodingrna
AT takanomotoki cot04circulatingbiomarkerforglioblastomaandprimarycentralnervoussystemlymphomanextgenerationsequencingofsmallnoncodingrna
AT yonezawaushio cot04circulatingbiomarkerforglioblastomaandprimarycentralnervoussystemlymphomanextgenerationsequencingofsmallnoncodingrna
AT sugiyamakazuhiko cot04circulatingbiomarkerforglioblastomaandprimarycentralnervoussystemlymphomanextgenerationsequencingofsmallnoncodingrna
AT taharahidetoshi cot04circulatingbiomarkerforglioblastomaandprimarycentralnervoussystemlymphomanextgenerationsequencingofsmallnoncodingrna